Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
This article was originally published in The Pink Sheet Daily
Phase III study found that sorafenib significantly improved overall survival and progression-free survival in patients with hepatocellular carcinoma.
You may also be interested in...
Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.